Patents Assigned to Teva Pharmaceutical Industries Ltd.
  • Publication number: 20220402875
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Application
    Filed: August 3, 2022
    Publication date: December 22, 2022
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • Publication number: 20210386690
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2021
    Publication date: December 16, 2021
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Patent number: 11135154
    Abstract: The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 360 mg/ml to 440 mg/ml medroxyprogesterone acetate, 1.35 mg/ml to 1.65 mg/ml docusate sodium, polyethylene glycol, and water. Methods of using these compositions are also described.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 5, 2021
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventor: Prakash Sundaramurthi
  • Publication number: 20210251921
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically accepable salt thereof.
    Type: Application
    Filed: May 3, 2021
    Publication date: August 19, 2021
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20210137852
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 13, 2021
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20210023026
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 8, 2020
    Publication date: January 28, 2021
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20200323796
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 26, 2020
    Publication date: October 15, 2020
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20200206161
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20200157052
    Abstract: The present invention relates to antagonists of the S1P3 receptor formula (A) as herein described and pharmaceutical compositions thereof. The compounds of formula (A) are useful in the preparation of a medicament, in particular for the treatment of Alzheimer's disease.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Chiara Caramelli, Cesare Federico, Emanuele Gabellieri, Matteo Magnani, Iolanda Micco, Georg C. Terstappen
  • Publication number: 20200093758
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 26, 2020
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20190365674
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 5, 2019
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20190262284
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 7, 2019
    Publication date: August 29, 2019
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20190142766
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 16, 2019
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20190117639
    Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 25, 2019
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventor: Michael HAYDEN
  • Patent number: 10232124
    Abstract: An injector device includes an injector body that receives a syringe; and an injection assembly being configured to dispense medicament from the syringe in a dispensation step. Certain types of injector devices include a sudden completion indicator that indicates when the injection is completed. Certain types of injector devices are configured to dispense two different medicament formulations having different viscosities from syringes without making any changes to the injector devices other than to switch out the syringes. Certain types of injector devices include safety arrangements that inhibit firing of the injector device until front and rear housing assemblies are disposed in predetermined rotational and axial positions relative to each other.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: March 19, 2019
    Assignee: Teva Pharmaceutical Industries, Ltd.
    Inventor: Toby Cowe
  • Publication number: 20190030016
    Abstract: This invention provides an isolated compound having the structure: or a salt thereof. The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 3, 2018
    Publication date: January 31, 2019
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventors: Malle Schmidt, Malle Päri, Marit Laos, Ants Maasalu, Kalle Kaljuste
  • Publication number: 20190000780
    Abstract: Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 13, 2018
    Publication date: January 3, 2019
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Eran Blaugrund, Ruth Levy
  • Publication number: 20180369228
    Abstract: This invention provides a method of treating a patient afflicted with a neurodegenerative disorder, e.g., Huntington's disease (HD), comprising administering to the patient laquinimod as an add-on therapy to or in combination with pridopidine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and pridopidine for treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention also provides laquinimod for use as an add-on therapy or in combination with pridopidine in treating a patient afflicted with a neurodegenerative disorder, e.g., HD. This invention further provides use of laquinimod and pridopidine in the preparation of a combination for treating a patient afflicted with a neurodegenerative disorder, e.g., HD.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Applicant: Teva Pharmaceutical Industries Ltd.
    Inventor: Michael HAYDEN
  • Patent number: 10130621
    Abstract: This invention provides an isolated compound having the structure: or a salt thereof. The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridne, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: November 20, 2018
    Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Malle Schmidt, Malle Päri, Marit Laos, Ants Maasalu, Kalle Kaljuste
  • Patent number: D936824
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: November 23, 2021
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventor: Mathew Donnelly